Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

SCD1 inhibitor MTI-301

An orally bioavailable stearoyl-CoA desaturase 1 (SCD1) inhibitor, with potential antineoplastic and immunomodulating activities. Upon oral administration, SCD1 inhibitor MTI-301 targets, binds to the saturated fatty acid (SFA) pocket and inhibits the activity of SCD1, thereby preventing the oxidation of SFAs to monounsaturated fatty acids (MUFAs). This prevents fatty acid synthesis in cancer cells and the fatty acid-mediated promotion of tumor growth, metastasis and drug resistance. This leads to endoplasmic reticulum (ER) stress and induces apoptotic cell death. Inhibition of SCD1 may also activate the adaptive immune response and may promote T-cell-mediated tumor immune responses. In addition, MTI-301 may sensitize cancers to immune checkpoint inhibitors. SCD1, an enzyme converting SFAs to MUFAs, promotes fatty acid synthesis in cancer cells and is upregulated in certain types of cancer. SCD1 plays a key role in tumor immunosuppression.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:stearoyl-CoA desaturase 1 inhibitor MTI-301
Code name:MTI 301
MTI-301
MTI301
SSI 4
SSI-4
SSI4
Chemical structure:2-{[4-(2-chlorophenoxy)piperidine-1-carbonyl]amino}-N-methylpyridine-4-carboxamide
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search